Insulet (PODD) AI Stock Analysis

• Market Cap: $20.31B
• Dividend Yield: N/A
• Average Volume (3M): 768.36K
• Price to Earnings (P/E): 84.0
• Beta (1Y): 0.69
• Revenue Growth: 27.12%
• EPS Growth: -41.72%
• Country: US
• Employees: 3,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.24
• Shares Outstanding: 70,346,900
• 10 Day Avg. Volume: 750,835
• 30 Day Avg. Volume: 768,355
• PEG Ratio: 0.43
• Price to Book (P/B): 15.10
• Price to Sales (P/S): 8.83
• P/FCF Ratio: 59.90
• Enterprise Value/Market Cap: 1.09
• Enterprise Value/Revenue: 8.76
• Enterprise Value/Gross Profit: 12.26
• Enterprise Value/Ebitda: 48.96
• 1Y Price Target: $379.53
• Price Target Upside: 31.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18
• EPS Forecast (FY): 4.88
• Revenue Forecast (FY): $2.69B

• Rating: 70 Outperform
• Price Target: $326.00 ▲(12.58% Upside)

Insulet's strong financial performance and positive earnings call highlight its growth potential, particularly in international markets. However, technical analysis indicates bearish trends, and the high P/E ratio suggests overvaluation. Recent strategic corporate appointments are positive but do not offset the technical and valuation concerns.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Insulet's products, enhancing its market position and supporting long-term financial health.

Product Innovation

Regulatory approval for Omnipod 5 enhancements strengthens Insulet's competitive edge in diabetes management, fostering future growth.

International Expansion

Strong international growth underscores Insulet's successful global expansion strategy, diversifying revenue streams and reducing market risk.

Negative Factors

Profit Margin Pressure

Decreasing profit margins may impact Insulet's profitability, challenging its ability to sustain operational efficiency and reinvest in growth.

Increased R&D Expenses

Rising R&D costs could pressure short-term profitability, though they may support long-term innovation and product development.

Higher Interest Expense

Increased interest expenses due to debt restructuring could strain cash flows, affecting financial flexibility and investment capacity.

Insulet Business Overview & Revenue Model

Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

How the Company Makes Money

Insulet generates revenue primarily through the sale of its Omnipod Insulin Management System, which includes the disposable Omnipod devices and the associated personal diabetes management software. The company earns revenue from both direct sales to patients and through partnerships with healthcare providers and payers that facilitate access to its products. Key revenue streams include the recurring revenue from the sale of disposable pods, which patients require on a regular basis, and revenue from the initial setup of the insulin management system. Additionally, Insulet collaborates with pharmaceutical companies and health systems to integrate its technology into broader diabetes care strategies, further contributing to its earnings.

Insulet Financial Statement Overview

Summary

Insulet demonstrates strong financial health with consistent revenue growth and improved leverage. While profitability margins have faced some pressure, operational efficiency remains high. The company's cash flow management is robust, supporting its financial stability and growth trajectory.

Income Statement

Insulet's income statement shows strong revenue growth with a 6.88% increase in TTM, supported by a solid gross profit margin of 71.47%. The net profit margin has decreased to 9.76% from the previous year's 20.19%, indicating some pressure on profitability. However, the company maintains a healthy EBIT margin of 8.93% and an EBITDA margin of 16.20%, reflecting operational efficiency.

Balance Sheet

The balance sheet indicates a significant improvement in financial stability, with a reduced debt-to-equity ratio of 0.06 in TTM, down from 1.17 the previous year. Return on equity stands at 18.27%, showcasing effective use of equity. The equity ratio is not provided, but the overall reduction in leverage is a positive sign.

Cash Flow

Cash flow analysis reveals a robust free cash flow growth rate of 8.47% in TTM, with a strong operating cash flow to net income ratio of 0.82. The free cash flow to net income ratio is 0.79, indicating efficient cash generation relative to net income. These metrics highlight improved cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.52B	2.07B	1.70B	1.31B	1.10B	904.40M
Gross Profit	1.80B	1.45B	1.16B	805.60M	752.10M	582.30M
EBITDA	451.20M	423.70M	323.60M	109.00M	139.60M	110.30M
Net Income	246.20M	418.30M	206.30M	4.60M	16.80M	6.80M
Balance Sheet
Total Assets	3.03B	3.09B	2.59B	2.25B	2.05B	1.87B
Cash, Cash Equivalents and Short-Term Investments	757.40M	953.40M	704.20M	674.70M	791.60M	947.60M
Total Debt	1.03B	1.42B	1.45B	1.43B	1.29B	1.08B
Total Liabilities	1.65B	1.88B	1.86B	1.77B	1.49B	1.27B
Stockholders Equity	1.38B	1.21B	732.70M	476.40M	556.30M	603.60M
Cash Flow
Free Cash Flow	421.20M	305.40M	70.10M	-38.30M	-190.80M	-82.50M
Operating Cash Flow	533.70M	430.30M	145.70M	119.00M	-68.10M	84.00M
Investing Cash Flow	-137.90M	-146.20M	-119.40M	-191.10M	-82.70M	14.00M
Financing Cash Flow	-543.70M	-28.10M	-13.60M	-40.30M	40.70M	605.50M

Insulet Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 289.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Negative. The current price of 289.57 is below the 20-day moving average (MA) of 310.19, below the 50-day MA of 317.24, and below the 200-day MA of 301.44, indicating a bearish trend. The MACD of -9.10 indicates Positive momentum. The RSI at 35.75 is Neutral, neither overbought nor oversold. The STOCH value of 4.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PODD.

Insulet Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	79 Outperform	$25.89B	36.59	30.63%	―	14.21%	5.66%
STE	77 Outperform	$24.83B	36.02	10.14%	0.95%	5.15%	60.30%
ZBH	73 Outperform	$18.02B	22.50	6.41%	1.05%	5.47%	-23.03%
PODD	70 Outperform	$20.31B	84.02	19.68%	―	27.12%	-41.72%
TNDM	61 Neutral	$1.53B	―	-109.73%	―	17.87%	-57.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHG	50 Neutral	$25.17B	-32.01	―	3.39%	-0.76%	-55.03%

Insulet Corporate Events

Insulet Appoints Robbie Huffines as New Director

On October 21, 2025, Insulet Corporation appointed Robbie Huffines as a Class II director, effective October 31, 2025. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase, brings extensive experience in healthcare investment banking to Insulet’s Board and will serve on its Audit Committee. This strategic appointment is expected to bolster Insulet’s growth and enhance shareholder value, as Huffines’ expertise aligns with the company’s mission of innovation and improving diabetes care.

Insulet Appoints New CFO Amid Revenue Growth

On September 16, 2025, Insulet Corporation announced the appointment of Flavia Pease as the new Chief Financial Officer, succeeding Ana Maria Chadwick. This transition is expected to ensure continued financial stability and growth, as Pease brings extensive experience from her previous roles at Charles River Laboratories and Johnson & Johnson. Additionally, Insulet anticipates exceeding its third-quarter 2025 revenue growth guidance, driven by strong new customer starts in both U.S. and international markets, which reflects positively on its market performance and future outlook.